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abstract | Rheumatic diseases are associated with high cardiovascular morbidity and mortality. Considerable 
differences exist in the frequency of cardiovascular disease (CVD) risk factors and events among people of 
different ethnic origins, but little is known of the ethnic variations in the relative distribution of CVD risk factors 
and the degree of atherosclerosis in patients with rheumatic diseases. Understanding this variation will 
provide insight into the underlying pathogenesis of CVD in patients with rheumatic diseases, and aid in future 
studies of the detection and management of this complication. In general, although Asian patients seem to 
have fewer background CVD risk factors and are less affected by metabolic syndrome (MetS) than their non‑
Asian counterparts, those with rheumatic disease are equally as susceptible to CVD. Furthermore, it seems 
that systemic inflammation and mechanisms that do not involve conventional CVD risk factors and MetS have 
an important role in the development of atherosclerosis in patients with rheumatic diseases. Here we examine 
the frequency of conventional CVD risk factors and the prevalence of MetS in both Asian and non‑Asian 
patients with selected rheumatic diseases. We also discuss the burden of CVD, as evaluated using various 
surrogate markers in these patients, and their overall CVD mortality rate.
Yiu, K.‑H. et al. Nat. Rev. Rheumatol. advance online publication XX Month 2011; doi:10.1038/nrrheum.2011.126
Introduction
the epidemiology of cardiovascular disease (CvD)1 and 
cardiovascular mortality2 in the general population varies 
across different ethnic groups owing to differences in both 
genetic and host susceptibility factors, dietary practice, and 
exercise.3,4 in particular, variation is observed between the 
frequency of CvD risk factors, such as type 2 diabetes mel-
litus (t2DM),5 metabolic syndrome (Mets)6 and smoking 
habit,7 across different ethnic groups. Population-based 
studies have shown the prevalence of CvD risk factors 
including hyperlipidemia, hypertension, t2DM and 
obesity, for example, is greater in patients from the usa 
than in those from China, although smoking is more 
prevalent in Chinese populations.8,9 indeed, in 2004, the 
reported 10-year coronary heart disease event rates for 
Chinese men and women were 1.5% and 0.6%, respec-
tively, in comparison with the corresponding event rates 
of 8.0% and 2.8% for us men and women.9 Despite this 
observation, differences in CvD risk factors and cardio-
vascular manifestations between asian and non-asian 
patients with rheumatic disease are not known.
accelerated atherosclerosis leading to premature CvD is 
recognized as a major cause of long-term morbitiy and mor-
tality in patients with rheumatic diseases, such as rheuma-
toid arthritis (ra), systemic lupus erythematosus (sLe) and 
systemic sclerosis (ssc).10–12 in addition to a high frequency 
of CvD risk factors, systemic inflammation has a pivotal 
role in the development of atherosclerosis in these patients.13 
in this review, we examine the potential differences in the 
prevalence of conventional CvD risk factors and Mets, the 
atherosclerotic burden (as assessed by various surrogate 
markers), and the epidemiology of CvD in patients with 
selected rheumatic disease. For the purposes of this review, 
we have focused on ra, sLe and ssc in asian and non-
asian populations; the populations studied and the main 
data gathered are summarized in Figure 1.
CVD risk factors in rheumatic disease
Rheumatoid arthritis
the conventional CvD risk factors, including t2DM, 
dyslipidemia and hypertension, were first studied when 
increased risk of CvD in patients with ra became 
evident. in a study by Gonzalez et al.,14 the prevalence of 
CvD risk factors was similar among 603 patients with ra 
and 603 non-ra controls (all from the usa), including 
t2DM (7% versus 7%, respectively), dyslipidemia (49% 
versus 52%) and hypertension (52% versus 49%). in the 
nurses’ Health study involving 114,342 us women, of 
whom 527 had ra, the incidences of t2DM (5% versus 
5%), dyslipidemia (35% versus 33%) and hypertension 
(34% versus 30%) were also similar among patients 
with or without ra, although patients with ra were 
more likely to have been smokers in their past (current 
smokers: 17% versus 20%; past smokers: 49% versus 
37%; P <0.01).15 Overall, these studies demonstrated that 
the prevalence of conventional CvD risk factors was 
similar in us patients with ra and non-ra controls, 
although patients with ra were probably more likely 
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than controls to be past smokers.15,16 However, increased 
disease duration might be associated with an increase in 
cardio vascular risk. in a separate us study evaluating 66 
patients with long-standing ra, 89 patients with early ra 
and 85 non-ra controls, several conventional CvD risk 
Key points
Cardiovascular‑related death is more prevalent in non‑Asian patients than in  ■
Asian patients, in whom death owing to infection is more likely, although direct 
comparison studies are needed
Conventional cardiovascular disease (CVD) risk factors, such as diabetes  ■
mellitus, dyslipidemia and hypertension, are similar between patients with or 
without rheumatic disease
The prevalence of metabolic syndrome varies between patients with rheumatic  ■
disease of different ethnicity, with Asian patients tending to be less affected 
than non‑Asian patients
On the basis of calcium score, carotid intima‑media thickness and detection  ■
of carotid plaque, Asian patients with rheumatic disease are as susceptible to 
CVD as their non‑Asian counterparts
Systemic inflammation has a prominent role in the development of  ■
atherosclerosis in Asian patients, despite their low background risk profiles
factors differed among the three groups (systolic blood 
pressure: 138 mm Hg versus 128 mm Hg versus 128 mm 
Hg, respectively, P = 0.01; smoking history: 30% versus 
21% versus 9%, respectively, P <0.01).17 in addition, this 
study also evaluated patients’ Framingham risk score—an 
index to predict cardiovascular risk that includes assess-
ment of age, gender, smoking habit, blood pressure and 
cholesterol concentrations. the Framingham risk score 
also estimates the risk of coronary events by stratifying 
indivi duals into three risk categories: low (<10% risk of 
an event in 10 years), intermediate (10% to 20% risk), and 
high (>20% risk).18 Overall, patients with long-standing 
ra had higher Framingham risk scores than patients with 
early disease or non-ra controls (14 versus 11 versus 12 
units; P <0.01).17 in contrast to non-asian populations, 
Mok and colleagues19 compared Chinese patients with ra 
with non-ra controls and found that the prevalence of 
elevated fasting glucose level (≥5.6 mmol/l; 16% versus 
22%, P <0.01) and dyslipidemia (high triglyceride level; 
12% versus 20%, P <0.01; low high-density lipoprotein 
level: 17% versus 46%, P <0.01) were lower in those with 
ra. However, the prevalence of hypertension was highest 
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Figure 1 | Summary of known risk factors for, surrogate markers of, and epidemiology of CVD in Asian and non‑Asian 
populations with RA, SLe or SSc. The countries in which the studies mentioned in this Review were conducted are indicated 
on the map. Fewer data exist for patients with SSc than for those with SLe or RA, and for Asian populations in comparison 
with non‑Asians. Data on cardiovascular causes of death in Asian patients with rheumatic diseases are scarce, and no 
direct comparisons have been carried out between Asian and non‑Asian populations. In general, Asian patients with SLe or 
RA seem to have fewer traditional CVD risk factors than their non‑Asian counterparts, but (according to surrogate markers 
of CVD) are as susceptible to development of CVD. Further studies are needed to clarify whether genetic differences and/
or diagnosis or treatment related factors boost the CVD risk of Asian patients with rheumatic diseases above the level 
predicted by traditional risk factors. Abbreviations: CVD, cardiovascular disease; RA, rheumatoid arthritis; SSc, systemic 
sclerosis; SLe, systemic lupus erythematosus.
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in patients with ra (52% versus 45%, P = 0.01), similar to 
non-asian populations.
the relative effect of conventional CvD risk factors on 
the development of adverse cardiovascular events seems 
to be less prominent in patients with ra than in non-ra 
controls. Gonzalez et al.14 found that the influence of 
CvD risk factors on combined cardiovascular outcome 
(myocardial infarction, heart failure and cardiovascular 
death) was lower in patients with ra than in non-ra con-
trols (t2DM: hazard ratio [Hr] 1.62 versus 2.05, P = 0.16; 
dyslipidemia: Hr 0.92 versus 1.14, P = 0.44; hypertension: 
Hr 1.97 versus 2.75, P = 0.30 and smoking history: Hr 
1.32 versus 2.19, P <0.01). although there is a paucity of 
data available for asian patients with ra in this regard, 
the evidence suggests that competing mechanisms, 
including high-grade systemic inflammation might have 
a more prominent role in the development of CvD in 
these patients, as opposed to individual CvD risk factors 
that have more influence in non-asian populations.
Systemic lupus erythematosus
in a Canadian study comparing 250 patients with sLe 
with 250 non-sLe controls, t2DM (5% versus 1%, 
P <0.01) and hypertension (33% versus 13%, P <0.01) 
were more prevalent in those with sLe. Conversely, 
dyslipidemia (34% versus 36%) and smoking history 
(17% vs. 20%) were similar between patients with or 
without sLe.20 in comparison with the 5% of us patients 
with t2DM,20 a study of 588 Korean patients with sLe 
reported that the prevalence of t2DM was 1%21, and in 
another study of 242 Chinese patients with sLe, t2DM 
was reported in 2% of the patients.22 However, no study 
has directly compared conventional CvD risk factors 
of asian patients with sLe with well-matched non-sLe 
controls. Furthermore, because of different disease char-
acteristics, a valid conclusion of potential differences in 
conventional CvD risk factors cannot be drawn between 
non-asian and asian sLe populations. although it is 
known that the increased incidence of CvD and pre-
mature atherosclerosis in sLe cannot be fully accounted 
for by conventional CvD risk factors, recommenda-
tions from the european League against rheumatism 
(euLar) have suggested the need for monitoring and 
treating conventional CvD risk factors according to 
existing guidelines.23,24
Systemic sclerosis
in a study performed in the Mediterranean region by 
tsifetaki et al.,25 60 patients with ssc exhibited mild dys-
lipidemia with lower serum levels of high-density lipo-
protein (HDL) and higher triglyceride  levels than 51 
non-ssc controls. in addition, the atherogenic low density 
lipoprotein (LDL):HDL ratio was considerably higher in 
those with ssc.25 a separate study comparing 49 Dutch 
patients with ssc with 32 non-ssc controls found that 
those with ssc had a lower HDL level (1.4 mmol/l versus 
1.7 mmol/l, respectively, P <0.03) and a higher triglycer-
ide level (1.4 mmol/l versus 1.2 mmol/l, P = 0.03).26 On 
the other hand, the prevalence of t2DM (4% versus 0%), 
systolic blood pressure (120 mmHg versus 120 mmHg) 
and diastolic blood pressure (75 mmHg versus 75 mmHg) 
were similar between both patient groups.
in a study by Mok et al.,27a comparison of 53 Chinese 
patients with ssc and 106 non-ssc controls found that 
patients with ssc were more likely to have lower LDL 
(2.4 ± 0.6 mmol/dl versus 2.8 ± 0.7 mmol/dl, respec-
tively, P <0.01) and HDL (1.4 ± 0.4 mmol/dl versus 
1.6 ± 0.4 mmol/dl, P = 0.01) levels. Moreover, blood pres-
sure was lower in those with ssc, an observation that 
could be attributed to a higher frequency of vasodilator 
use in this patient group (70% versus 23%, P <0.01).27 
nevertheless, the prevalence of t2DM was similar 
between patients with or without ssc (7.5% versus 11.3%). 
although the combined data suggest that for patients with 
ssc, those from asian populations have lower conven-
tional CvD risk factors (such as dyslipidemia and blood 
pressure) than those from a non-asian background, larger 
studies are needed to validate this conclusion.
MetS in rheumatic disease
Mets is a combination of medical disorders (includ-
ing hypertension, diabetes, dyslipidemia and central 
obesity) that increases the risk of future cardiovascular 
events. two of the most commonly used definitions for 
the diagnosis of Mets include the wHO criteria28 and 
the national Cholesterol education Program adult 
treatment Panel (nCeP) iii criteria, both of which 
involve the assessment of fasting glucose, dyslipidemia, 
hypertension and central obesity [Au: OK?].29 Mets is 
a common presentation in patients with rheumatic dis-
eases and represents an important risk for developing 
atherosclerosis. However, variable environmental factors, 
including the consumption of dairy-related products, 
might lead to differences in the prevalence of Mets 
between ethnic groups.
Rheumatoid arthritis
whereas individual conventional CvD risk factors seem 
to be similar between patients with ra and non-ra 
individuals, Mets is more prevalent in us patients with 
long-standing ra or early ra than in non-ra controls 
(wHO criteria: 42% versus 31% versus 11%, respec-
tively, P <0.001; nCePiii criteria: 42% versus 30% versus 
22%, P = 0.03).30 in another study, Karvounaris and col-
leagues31 evaluated the prevalence of Mets in 200 patients 
with ra (with a mean age of 63) and 400 age-matched 
non-ra controls in the Mediterranean region. although 
the overall prevalence of Mets was similar between both 
patient groups (44% versus 41%, respectively), those 
with ra who had Mets were more likely to have high 
ra disease activity than those without Mets.
in a study of 699 Chinese patients with ra, Mok et al.19 
determined that up to 20% of these patients had Mets, 
which was not higher than the frequency in the general 
population. in agreement with this finding, another 
study by Karimi et al.32 found that the frequency of Mets 
in patients with ra from iran was also similar to the 
frequency in non-ra controls. However, the duration 
of disease among those with ra was associated with an 
increased frequency of Mets, suggesting a pivotal role of 
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chronic inflammation in the development of this disease 
complex.
interestingly, a study performed by Dessein et al.33 in 
74 patients with ra showed that individual Mets fea-
tures, including hypertension, insulin resistance and 
high triglycerides, were more strongly associated with 
subclinical atherosclerosis than the currently recom-
mended Mets definitions for subclinical atherosclero-
sis. similarly, another study involving 631 patients with 
ra showed that individual CvD risk factors (diabetes, 
dyslipidemia, hypertension and smoking) contributed 
to carotid intima-media thickness (iMt) and the pres-
ence of carotid plaque.34 Data from the Consortium 
of rheumatology researchers of north america 
(COrrOna) registry, which involves over 10,000 us 
patients with ra, demonstrated that increased markers 
of severity of ra, in addition to conventional CvD 
risk factors, were associated with an increase in cardio-
vascular risk. in particular, patients with no risk factors 
or markers of ra severity had an incidence rate of zero 
(95% Ci 0–5.98) cardiovascular events per 1,000 person-
years, whereas patients with at least two traditional CvD 
risk factors and three or more markers of ra severity 
had an incidence rate of 7.47 (95% Ci 4.21–10.73) per 
1,000 person-years.35 therefore, these data suggest that 
conventional CvD risk factors and Mets both contribute 
to the development of premature atherosclerosis in ra.
Systemic lupus erythematosus
similarly to studies in patients with ra, previous reports 
have demonstrated that patients with sLe have a higher 
prevalence of Mets than non-sLe controls. Chung et al.36 
reported a higher prevalence of Mets in 102 us patients 
with sLe than in 101 non-sLe controls (wHO criteria: 
32.4% versus 10.9%, respectively, P <0.001), although 
this difference was not significant according to nCePiii 
criteria (29.4% versus 19.8%). that these latter criteria 
do not include assessment of insulin resistance, which 
is associated with systemic inflammation, might explain 
why their use finds a lower prevalence of Mets than use 
of the wHO criteria [Au:OK?]. a spanish study also 
reported that 160 young patients with sLe patients had 
a higher prevalence of Mets compared with 245 age-
matched non-sLe controls (nCeP-atPiii criteria: 15.8% 
vs. 4.2%, respectively, P <0.001).37
Few relevant studies have been carried out in asian 
patients with sLe. However, in another study by Mok 
et al.38 evaluating 123 Chinese patients with sLe, the 
prevalence of Mets was higher in these individuals than 
in 492 non-sLe controls (16.3% versus 9.5%, respectively 
P <0.05). in addition, patients with Mets had higher levels 
of high-sensitive C-reactive protein, homocysteine and 
soluble thrombomodulin than those without Mets.
Systemic sclerosis
to our knowledge, no direct studies have evaluated Mets 
in patients with ssc in both non-asian and asian popula-
tions. Overall, although ethnic studies on the prevalence 
of Mets in patients with various rheumatic diseases have 
not been conducted, the incidence of Mets in the general 
population seems to be lower among asian populations 
than in non-asian populations, a finding that might be 
related to ethnic differences in dairy-related product 
consumption and the incidence of obesity.39,40 this phe-
nomenon suggests that asian patients with rheumatic 
disease might be at a lower risk of developing CvD 
than their non-asian counterparts. Further studies are 
required, however, for a more detailed evaluation of the 
incidence of Mets in patients with rheumatic diseases 
across different ethnicities.
CVD markers in rheumatic disease
Large, long-term cohort studies are required to deter-
mine the true prevalence of CvD in patients of differ-
ent ethnicities with rheumatic disease. in the absence of 
these studies (many of which are underway), the detec-
tion of surrogate markers of CvD enables clinicians to 
evaluate the burden of cardiovascular complication in 
these patients.
Coronary artery calcification
the advent of multi-detector computed tomography 
(MDCt) allows rapid, effective and noninvasive detec-
tion of the extent and severity of atherosclerosis in vas-
cular beds by imaging arterial calcification to reflect the 
presence of calcified atherosclerotic plaques. Previous 
studies have shown that the presence of coronary and 
aortic calcification detected by MDCt is predictive of 
major cardiovascular events.41,42
Rheumatoid arthritis
in a report by Chung et al.,43 us patients with early ra or 
established ra had a higher prevalence of coronary cal-
cification compared with non-ra controls (42.9% versus 
60.6% versus 38.4%, respectively, P = 0.016). Moreover, 
severe coronary calcification (as defined by an agatston 
coronary calcification score [CCs]>109) was 3.4-fold 
higher in patients with established ra than in non-ra 
controls. the presence of coronary calcification in ra 
patients has also been shown to be associated with longer 
disease duration.44
similar to non-asian patients, our group has recently 
demonstrated that 85 patients with ra from Hong Kong, 
when compared with 85 non-ra controls, had a fivefold 
higher prevalence (CCs >0) and extent (CCs 63 ± 197 
versus 11 ± 39, P <0.01) of coronary calcification as 
detected by MDCt.45 Moreover, our study has further 
described that the presence and extent of arterial calci-
fication in patients with ra was not only limited to the 
coronary vessel but was found across the whole vascular 
bed including the aorta and the carotid artery.
Systemic lupus erythematosus
in a 2002 report by von Feldt et al.46 studying 13 us 
patients with sLe, it was revealed that five of these 
patients had a CCs in the 70th percentile compared with 
historic age-matched women without known coronary 
artery disease and without sLe. this finding of high 
coronary calcification has been further confirmed by 
a study comparing 65 us patients with sLe with 69 
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non-sLe controls, which demonstrated up to a 10-fold 
higher risk of coronary calcification (CCs >0) in those 
with sLe as detected by MDCt.47 Moreover, the mean 
CCs was higher in patients with sLe than in non-sLe 
controls (69 ± 244 versus 9 ± 42, respectively, P <0.01).
we have also demonstrated that the presence of 
coronary calcification (CCs >0) was 30-fold higher in 
50 Chinese patients with sLe when compared with 50 
non-sLe controls.48 Moreover, the prevalence and extent 
of vascular calcification in the rest of the systemic vascu-
lar tree including the thoracic aorta and the carotid arter-
ies were higher in those patients with sLe. these findings 
suggest that for patients with sLe, Chinese patients are as 
susceptible to CvD as their non-asian counterparts. it 
must be stressed, however, that since only a few MDCt 
studies have been performed so far in patients with sLe, 
and the number of included patients is low, caution is 
needed when comparing the frequency of CvD between 
asian and non-asian patients on the basis of MDCt 
studies. indeed, much larger studies are required.
Systemic sclerosis
in a study comparing 17 us patients with ssc with 17 
non-ssc controls, coronary calcification (CCs >0) was 
more prevalent in those with ssc (56.2% versus 18.8%, 
respectively, P = 0.03).49 Moreover, the severity of CCs 
was also greater in these patients (126.6 ± 251.0 versus 
14.7 ± 52.2, P = 0.003).
similarly, we studied 53 Chinese patients with ssc and 
found that up to 57% of them had severe coronary calci-
fication (CCs ≥101), which was higher than the observed 
coronary calcification in non-ssc controls.27 Multivariate 
analysis demonstrated that ssc was an independent risk 
factor for severe coronary calcification. this study has 
further suggested that ssc was associated with coronary 
atherosclerosis in asian patients, similar to non-asian 
patients, even after the data was controlled for conven-
tional CvD risk factors.
Carotid intima‑media thickness
Carotid iMt is a well-validated surrogate marker for 
preclinical atherosclerosis and a predictor of future 
cardiovascular events.50 the ability to measure arterial 
intima-media wall thickness enables early detection 
of atherosclerosis and allows quantification of athero-
sclerotic burden. By contrast, an invasive angiogram 
might only detect the late stages of atherosclerosis that 
cause significant luminal obstruction. a number of 
studies have been carried out in patients with rheumatic 
disease using carotid iMt and the prevalence of carotid 
plaque as surrogate markers for premature atherosclero-
sis (table 1). in addition, a meta-analysis of data from 25 
studies of ra, 24 studies of sLe and six studies of ssc has 
shown that patients from all three groups of rheumatic 
disease have a higher carotid iMt than nonrheumatic 
controls.51
Rheumatoid arthritis
Carotid iMt and the prevalence of carotid plaque 
are among the most commonly evaluated surrogate 
markers of CvD in patients with ra. in a swedish trial, 
39 patients with ra had a greater carotid iMt than 39 
non-ra controls.52 Furthermore, carotid iMt correlated 
positively with abnormal lipid profile and tissue plasmi-
nogen activator antigen, a marker of thrombotic activ-
ity. another study evaluating 84 patients with ra from 
Greece demonstrated that the carotid iMt and the preva-
lence of carotid plaque were both higher when compared 
with non-ra controls.53 Moreover, patients with ra had 
a similar carotid iMt and prevalence of carotid plaque 
when compared with age-matched and gender-matched 
patients with t2DM, suggesting that both diseases con-
tribute equally to the development of preclinical athero-
sclerosis. On the other hand, in a large study performed 
in the usa, carotid iMt was not found to be similar in 
patients with or without ra.54 Carotid iMt, however, 
correlated positively with inflammatory markers both in 
patients with ra and in non-ra controls, a finding that 
is consistent with the hypothesis that systemic inflamma-
tion has a significant role in the development of athero-
sclerosis. Other studies in non-asian patients with ra 
have also demonstrated that the prevalence of carotid 
iMt and the presence of carotid plaque were both higher 
in these patients than in non-ra controls (table 1).55–57
studies involving asian populations have consis-
tently demonstrated a similar increase in carotid iMt 
in those with ra compared with non-ra controls.58–61 
in a Japanese study by Kumeda et al.,58 carotid iMt in 
patients with ra was higher than in non-ra controls. 
Moreover, high carotid iMt was associated with an 
increased disease duration and disease activity. in another 
report published by the same group,60 it was shown 
that female Japanese patients with ra had a greater 
increase in carotid iMt than their non-ra counter-
parts (0.027 ± 0.046 mm/year versus 0.001 ± 0.059 mm/
year, respectively, P = 0.0074), which was positively cor-
related with disease activity. in a separate study carried 
out in Korea, postmenopausal female patients with ra 
had increased carotid iMt when compared with non-ra 
controls.59 Furthermore, no differences in carotid iMt 
were observed in this study between patients who were 
or were not receiving methotrexate or steroids.
Systemic lupus erythematosus
a study of female swedish patients with sLe found 
that carotid iMt was increased in the subgroup who 
developed CvD, in comparison either with the patients 
without CvD or with non-sLe controls.62 Patients with 
sLe but without CvD had a similar carotid iMt thick-
ness to non-sLe controls, but with a higher prevalence of 
carotid plaque. in a study involving 197 us patients with 
sLe, roman and colleagues63 demonstrated that patients 
with sLe had a higher prevalence of carotid plaque than 
non-sLe controls (multivariate adjusted odds ratio 4.8). 
similarly, thomsom et al.64 demonstrated a higher preva-
lence of carotid plaque in us patients with sLe than in 
non-sLe controls, further suggesting that early onset of 
premature atherosclerosis occurs in patients with sLe.
in a study comparing 32 Chinese patients with sLe 
with 32 non-sLe controls, carotid iMt was found to be 
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greater in those with sLe.65 Moreover, patients with a 
high disease activity (as defined by an sLe disease activ-
ity index [sLeDai] score ≥3) had greater carotid iMt 
than patients with stable disease (sLeDai <1). Moreover, 
Zhang et al.66 found that carotid iMt was higher and 
the prevalence of carotid plaque was more frequent in 
111 premenopausal Chinese patients with sLe than in 40 
non-sLe controls. these studies highlight that in asian 
populations, carotid iMt is greater and the presence 
of plaque is more frequent in patients with sLe than in 
non-sLe controls, suggesting that the rate of accelerated 
atherosclerosis in sLe might be similar to that observed 
in non-asian populations.
Systemic sclerosis
in a european study, Hettema et al.26 showed that the 
carotid iMt was similar in patients with or without ssc 
(0.69 mm versus 0.68 mm, respectively. On the other 
hand, in a study of 60 patients with ssc from Greece, 
carotid iMt was found to be higher in these patients 
than in non-ssc controls (0.77 mm versus 0.59 mm, 
P <0.0001).25 the reason for the discrepancy between 
these findings is unknown and will require exploration 
in future studies.
to our knowledge, no studies to date have evaluated 
carotid iMt in asian ssc populations, and no major 
studies have assessed other surrogate markers of CvD 
risk in such cohorts [Au:OK?]. an effort to examine the 
degree of carotid atherosclerosis in this group of patients is 
needed and will highlight any potential ethnic differences 
between asian and non-asian populations with ssc.
CVD epidemiology in rheumatic disease
Rheumatoid arthritis
CvD represents a major cause of morbidity and mortal-
ity in patients with ra. Community-based studies in the 
usa have consistently found that patients with ra have 
an increased risk of cardiovascular events (table 2).15,67 in 
Table 1 | Studies of carotid IMT in patients with RA, SLe or SSc from different ethnic backgrounds
Study population Carotid imt (mm) Carotid Plaque (%)
ethnicity Controls Patients Controls Patients Relative increase 
(%)/ (P‑value)
Controls Patients P‑value
RA
Swedish52 n = 39; mean age 52; 
30% male
n = 39; mean age 
52; 30% male
0.70 ± 0.03* 0.79 ± 0.04* 12.8 (0.05) ND ND ND
US54 n = 102; mean age 60; 
11% male
n = 204; mean age 
60; 12% male
0.98 ± 0.45‡ 1.03 ± 0.43‡ 5.1 (0.30) 25 30 0.28
US57 n = 105; mean age 47; 
2% male
n = 80; mean age 
45; 2% male
0.71 ± 0.17‡ 0.64 ± 0.17‡ –9.8 (0.01) 15 44 <0.01
Greek53 n = 84; mean age 63; 
29% male
n = 84; mean age 
64; 29% male 
0.65 ± 0.15‡ 0.75 ± 0.15‡ 15.3 (<0.01) 9.5 47.6 <0.01
Slovenian56 n = 40; mean age 42; 
0% male
n = 70; mean age 
42; 0% male
0.47 0.59 25.5 (<0.01) ND ND ND
Mexican55 n = 20; mean age 41; 
0% male
n = 55; mean age 
44; 0% male
0.58 ± 0.10‡ 0.67 ± 0.18‡ 15.5 (0.01) ND ND ND
Japanese58 n = 138; mean age 55; 
12% male
n = 94; mean age 
52; 10% male
0.58 ± 0.12‡ 0.64 ± 0.13‡ 10.3 (<0.01) ND ND ND
Korean59 n = 53; mean age 55; 
0% male
n = 53; mean age 
55; 0% male
0.68 ± 0.14‡ 0.77 ± 0.09‡ 13.2 (<0.01) 0 1.9 >0.05
SLE
Swedish62 n = 26; mean age 52; 
0% male
n = 26; mean age 
52; 0% male
0.59 ± 0.12‡ 0.66 ± 0.15‡ 11.9 (0.03) 11.5 65.4 <0.05
US63 n = 197; mean age 44; 
6% male
n = 197; mean age 
44; 6% male
0.61 ± 0.16‡ 0.67 ± 0.14‡ –11.4 (<0.01) 15.2 37.1 <0.01
American64 n = 104; mean age 44; 
0% male
n = 217; mean age 
45; 0% male
0.63 ± 0.08‡ 0.63 ± 0.13‡ 0 (0.71) 17 31 <0.01
Chinese66 n = 40; mean age 36; 
0% male
n = 111; mean age 
34; 0% male
0.45 (IQR 
0.38‑0.48) 
0.62 (IQR 
0.55‑0.67)
37.7 (<0.01) 0 14.4 <0.01
Japanese61 n = 22; mean age 57; 
0% male
n = 25; mean age 
58; 0% male 
0.7 ± 0.2 1.3 ± 0.7 71.4 (<0.01) ND ND ND
SSc
Dutch26 n = 32; mean age 51; 
9% male
n = 49; mean age 
55; 16% male
0.68 (IQR 
0.56‑0.75)
0.69 (IQR 
0.62‑0.79)
1.4 (0.07) ND ND ND
Greek25 n = 54; age and gender 
unclear[Au: OK?]
n = 54; age and 
gender unclear
0.59 ± 0.14‡ 0.77 ± 0.2‡ 30.5 (<0.01) ND ND ND
*Standard error of mean. ‡Standard deviation. Abbreviations: IMT, intima media thickness; IQR, interquartile range; ND, not determined; RA, rheumatoid arthritis; SLe, systemic lupus 
erythematosus; SSc, systemic sclerosis.
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addition, a retrospective study by Maradit-Kremers et al.68 
showed that us patients with ra were twice as likely to 
have unrecognized myocardial infarctions, even before 
the diagnosis of ra, and sudden deaths compared with 
non-ra controls. Currently, no data are available concern-
ing the exact risk of cardiovascular events in asian patients 
with ra compared with non-ra controls. a study by Mok 
and colleagues,69 however, showed that the standard-
ized mortality rate (sMr) in Chinese patients with ra 
was 1.7 (95% Ci 1.6–1.8), with infection being the most 
common cause of death, followed by cardiovascular events 
and stroke (34% versus 12% versus 7%, respectively). an 
accurate evaluation of ethnic differences in cardiovascular 
causes of death in ra requires future exploration.
Systemic lupus erythematosus
similarly to individuals with ra, patients with sLe have 
a higher risk of cardiovascular events than non-sLe 
controls. a 1976 study by urowitz et al.11 identified a 
bimodal mortality pattern in patients with sLe. On the 
basis of the Framingham Offspring study carried out in 
the usa, young women with sLe were particularly more 
likely to have a myocardial infarction than age-matched 
non-sLe controls (35–44 year age group relative risk 
[rr] 52.4, 95% Ci 21.6–98.5; 45–54 year age group rr 
2.47, 95% Ci 0.8–6.0; 55–64 year age group rr 4.21, 95% 
Ci 1.7–7.9).70 in the nurses’ Health study, us patients 
with sLe had a rr of 2.25 for coronary artery disease 
and a rr of 2.29 for stroke, after adjustment for con-
founding factors and ethnicities (95% white, 4% black 
and 1% others) (table 2).71 in another european study 
involving over 4,000 patients with sLe, the major cause 
of death was attributable to CvD, with up to a 16-fold 
increased risk of death from coronary heart disease in 
young patients with sLe (aged 20–39 years) in compari-
son with the general population.72 although the overall 
all-cause mortality in sLe has declined over the past 
20 years, the risk of mortality associated with ischemic 
heart disease remains unchanged.
Data comparing cardiovascular causes of death 
between asian patients with or without sLe are scarce. 
a study comparing 5,243 Chinese patients with sLe with 
the general population found a higher sMr in those with 
sLe (5.25, 95% Ci 4.79–5.70), of which the most likely 
cause of death was infection, followed by cardiovascu-
lar and cerebrovascular events (22% versus 10% versus 
6%, respectively).69 similarly, another prospective study 
involving 285 Chinese patients with sLe who were 
assessed for up to 15 years showed that the major cause 
of death was attributable to infections, followed by CvD 
and cerebrovascular complications (55% versus 17% 
versus 14%).73 although the study population was small 
compared with other studies conducted in non-asian 
populations, the potential discrepancies in the causes of 
mortality between ethnicities, particularly those that are 
CvD-related, require further exploration.
Systemic sclerosis
in patients with ssc, the major causes of mortality are 
disease-related complications, including interstitial 
lung disease, pulmonary hypertension and renal crisis. 
to our knowledge, no studies have specifically evaluated 
the cardiovascular risk in patients with ssc compared 
with non-ssc controls, in either asian or non-asian 
populations. a previous report suggested a possible 
increase in CvD or cerebrovascular disease in ssc,74 and 
other studies have demonstrated that the rate of CvD 
is increased in patients with ssc. a uK cohort study 
involving 283  patients with ssc demonstrated a fourfold 
increase in mortality in ssc (female sMr 4.6, 95% Ci 
3.2–6.2; male sMr 3.2, 95% Ci 1.8–5.0) and almost 30% 
of these deaths were attributable to CvD-related events.75 
in a Danish trial involving 344 patients with ssc, 30% of 
the mortalities were cardiovascular in origin.76 a study of 
Table 2 | Studies of cardiovascular risk in patients with RA or SLe
ethnicity Study type Controls Patients Follow‑up 
(years)
adjusted relative risk (Ci)
RA
US15 Prospective 
cohort study
n = 113,815; mean 
age 56, 0% male
n = 527; mean age 
58, 0% male
21 MI, 2.0 (1.2–3.3), P <0.01; stroke, 
1.5 (0.7–3.1), P = 0.31
US67 Cross‑sectional 
study
n = 2,479; mean 
age 66, 18% male
n = 9,093; mean 
age 60, 23% male 
NA MI, 2.1 (1.5‑2.9), P <0.05; stroke, 
1.7 (1.3‑2.4), P <0.05
US68 Retrospective 
cohort study
n = 603; mean age 
58; 27% male
n = 603; mean age 
58; 27% male
NA Unrecognized MI, 2.13 (1.13‑4.03), 
P <0.05; sudden death, 1.94 
(1.06–3.55), P <0.05
SLE
US71 Prospective 
cohort study
n = 119,184; mean 
age 56; 0% male
n = 148; mean age 
53; 0% male
28 CAD, 2.25 (1.37–3.69), P <0.01; 
stroke, 2.29 (0.85–6.15), P = 0.10
Swedish72 Retrospective 
cohort study
SMR of the general 
population 
n = 4,737; age 
20–39 (27%), 
40–59 (35%), >60 
(38%), 22% male
≤31 CAD SMR, 3.0 (2.8–3.1), P <0.05; 
stroke SMR, 2.1 (1.7–2.4), P <0.05
Abbreviations: CAD, coronary artery disease; MI, myocardial infarction; NA, not applicable; RA, rheumatoid arthritis; SLe, systemic lupus erythematosus; SMR, 
standardized mortality rate.
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the euLar scleroderma trials and research (eustar) 
cohort, a multinational, prospective cohort involving 
5,860 european patients with ssc, demonstrated that up 
to 5% of all-cause mortalities were attributable to myo-
cardial infarction and 3% to stroke.77 this comparatively 
lower prevalence of CvD mortality might be explained 
by the multi-ethnic nature of the eustar registry, and 
potentially by changes in the pattern of mortality (due to 
advances in the treatment of ssc) being reflected in this 
more recent study [Au:OK?].77
Data concerning cardiovascular-related mortality in 
asian patients with ssc are limited. a study involving 449 
Chinese patients with ssc found that the sMr compared 
with the general population was 3.9 (95% Ci 3.2–4.7).69 
the most common cause of death was due to infection, 
closely followed by cardiovascular cause and stroke (17% 
versus 16% versus 3%, respectively).
Considering the potential differences in CvD risk 
factors between non-asian and asian patients with rheu-
matic disease, a difference regarding cardiovascular-related 
mortality might be expected. unfortunately, such data in 
asian populations are sparse, and any conclusions must be 
drawn with caution. while we await the implem ntation 
and reporting of large long-term cohort studies—some of 
which are underway—on the frequency of CvD and its 
associated risk factors in asian rheumatic disease popu-
lations, it is worth noting that surrogate markers of CvD 
are similarly increased in asian and non-asian patients in 
comparison with nonrheumatic controls.
Possible causes of ethnic differences
Factors that might explain ethnic differences in the cardio-
vascular risk in patients with rheumatic disease include 
differences in epidemiologic transition, psychosocial 
stress burden and genetic make-up between asian and 
non-asian patients. For example, it has been shown that 
in european patients with sLe, low-expression genotypes 
for mannose-binding lectin gene (MBL2), and hence low 
levels of MBL, were correlated with carotid iMt, indepen-
dent of conventional CvD risk factors.78 Furthermore, in 
the PrOFiLe study involving a multiethnic prospective 
cohort of patients with sLe, the incidence of overall vas-
cular events (myocardial infarction ± vascular procedures, 
stroke, claudication or significant gangrene of extremi-
ties) were similar between different ethnic groups, but 
the presence of CRP2*C allele (rs1800947) was associated 
with a shorter time to the occurrence of arterial vascu-
lar events (Hr = 1.75, 95% Ci 1.00–3.07).79 the implica-
tions of these factors require further studies. in addition, 
certain rheumatic diseases, such as sLe, have anecdotally 
been reported to be more active and severe in asia.80 For 
example, the incidence of severe nephritis is believed to 
be higher in asian patients with lupus. the associated 
excessive inflammatory response and the use of high-
dose steroids and cytotoxic agents have been shown to 
accelerate the development of CvD[Au: ref?]. Further, 
although prompt effective control of underlying rheu-
matic disease is key to the prevention of cardiovascular 
events, the management of rheumatic diseases in many 
asian countries is suboptimal as a result of inadequate 
resources. indeed, many countries in the asia Pacific 
have failed to have rheumatology established as a subspe-
cialty in medicine. in the early 1990s, with the exception 
of developed countries such as australia, Japan and new 
Zealand, there were probably fewer than 100 fully trained 
and accredited rheumatologists for the whole of the asia-
Pacific region, with a population of nearly 3 billion people. 
Delay in the diagnosis and treatment of rheumatic diseases 
might explain the development of CvD complications in 
asian patients despite a lower incidence of conventional 
Cv risk factors.
Conclusions
Patients with rheumatic diseases are known to be at 
increased risk of the development of CvD, the mecha-
nism of which is thought to be related to excess inflam-
mation. the contribution of inflammation towards CvD 
development can be evaluated by studying patients of dif-
ferent ethnicities with rheumatic diseases. General popu-
lation studies have shown that asians, on the whole, are 
exposed to fewer CvD risk factors and are less susceptible 
to CvD deaths than their non-asian counterparts. indeed, 
studies have so far shown that asian patients with ra or 
sLe possess fewer traditional CvD risk factors such as 
t2DM, dyslipidemia and Mets than non-asian patients. 
However, using surrogate markers such as carotid iMt 
and CCs, asian patients with ra and sLe seem to be 
as susceptible to CvD development as their non-asian 
counterparts. Fewer and less comprehensive studies on 
CvD in ssc have been carried out so far. nevertheless, 
asian and non-asian patients with ssc probably have a 
similarly increased frequency of CvD, based on CCs mea-
surement. these observations suggest that inflammation 
and other immune mediated responses are important in 
CvD development in patients with rheumatic diseases, 
and that these factors have proportionately more influence 
in asian patients than their non-asian counterparts. it 
should, however, be noted that CvD epidemiology studies 
in asia are scarce and that direct comparisons of cardio-
vascular causes of death between asian and non-asian 
patients with rheumatic disease have not been conducted 
so far. these studies should be encouraged. Future studies 
should also focus on the relationship between the cumu-
lative burden of inflammation and CvD development, 
and the effects of aggressive treatment on the long-term 
cardio vascular outcome of rheumatic diseases. 
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